Home
Storia in 1 fonti
2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
Raccontata da
morningstar.com
- ·
2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits…
2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in…
- ·
2026 ASCO Abstract Highlights | Innovent Announces Preliminary PoC data of IBI363 (PD-1/IL-2α-bias bispecific fusion protein) in…
2026 ASCO Abstract Highlights | Innovent Announces Preliminary PoC data of IBI363 (PD-1/IL-2α-bias bispecific fusion protein) in Combination with Chemotherapy as First-line…
- ·
/C O R R E C T I O N — Innovent Biologics/
/C O R R E C T I O N -- Innovent Biologics/